Sunday, May 11, 2025
5/11/2025
Alcohol-induced Gut Dysbiosis and Cardiovascular Disease - PROJECT SUMMARY Hazardous alcohol use (HAU) leads to tremendous morbidity and mortality in millions of individuals in the United States and worldwide annually. The cognitive, neuronal, and psycho-social aspects of alcohol use have been well established. More recently, clinical, and basic research has begun to understand the role in which HAU contributes to gut dysbiosis, which plays a significant role in one’s overall health status. Furthermore, a large portion of deaths associated with alcohol use are related to digestive diseases. HAU predisposes and contributes to the manifestation of several comorbidities, like hypertension, metabolic syndrome, and diabetes mellitus which drive and exacerbate vascular dysfunction and cardiovascular disease (CVD). Previous research has demonstrated that the gut microbiome too plays a critical role in the diagnosis and prognosis of individuals with established CVD. Increased levels of circulating trimethylamine-N-oxide (TMAO), a gut derived metabolite, has been shown to drive the development of atherosclerotic heart disease. However, the relationship between HAU- induced gut dysbiosis and its’ metabolites towards vascular and CV function is not well-defined. We hypothesize that HAU-induced gut dysbiosis leads to endothelial dysfunction and increased risk of CVD via gut- derived metabolites (i.e., TMAO). Furthermore, we believe that HAU-induced gut dysbiosis exacerbates the progression of heart failure and that gut microbiota-targeted therapies (MBTT) will restore vascular function thereby improving CV health in the setting of HAU. Through utilization of mouse models of HAU and microbiota adoptive transfer we plan to execute a series of studies that demonstrate HAU-induced dysbiosis and CV-related pathology are related; moreover, that the dysbiotic microbiome is sufficient to cause the vascular dysfunction and increased risk of CVD. We plan to utilize metagenomics, metabolomics, and cardiovascular function assessment to demonstrate the causal relationship between HAU, the gut microbiome and CVD. We will then investigate the effects of prior HAU gut dysbiosis on the progression of heart failure in a murine model of myocardial ischemia-reperfusion (MI/R). This will answer questions regarding the predisposition of individuals who participate in HAU and their risk for worsening CV outcomes after MI/R-induced heart failure. Concurrently, we will examine continuous HAU prior to and after MI/R-induced heart failure to understand if HAU leads to increase morbidity or mortality in the presence of CVD. Successful completion of these studies will significantly advance our understanding of the pathology of alcohol-induced gut dysbiosis and its’ effects on vascular and cardiac function.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).